Press-release for stocks related to therapeutics

Prices are updated after-hours

tags : Therapeutics

save search

Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 0.01% | O: 2.24% H: 0.0% C: -0.8%
AZNCF | $138.24 -4.19% 800

Health Technology

| 1.57% | O: -3.43% H: 6.21% C: 6.21%
VTRS | $11.25 1.17% 1.16% 4.7M

Health Technology

| -5.76% | O: -0.25% H: 1.1% C: -0.17%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -2.83% | O: -0.05% H: 0.43% C: -0.27%
BMY | $48.93 1.3% 0.0% 10M

Health Technology

| -5.88% | O: -0.08% H: 0.04% C: -0.35%
BHC | $8.63 0.35% 2.1M

Health Technology

| -16.04% | O: 0.38% H: 0.0% C: -7.27%
ABBV | News | $166.41 1.06% 0.0% 5.5M

Health Technology

| -1.64% | O: 0.77% H: 1.63% C: 0.35%
SNY | News | $46.385 2.19% 3M

Health Technology

| -3.02% | O: 0.84% H: 0.0% C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M

Health Technology

| 1.21% | O: 0.18% H: 0.3% C: 0.19%
eczema dermatitis set therapeutics market

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
Published: 2024-04-08 (Crawled : 17:00) - globenewswire.com
INKT | $0.898 3.02% 38K

| -41.03% | O: 1.28% H: 0.0% C: -16.46%
nk-215 liver cancer preclinical therapeutics

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor
Published: 2024-04-08 (Crawled : 14:00) - biospace.com/
CCCC | $6.74 -2.46% -2.52% 1.7M

Health Technology

| -9.79% | O: -1.57% H: 0.0% C: 0.0%
cft1946 approved preclinical for therapeutics

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Published: 2024-04-08 (Crawled : 13:30) - biospace.com/
COYA | News | $7.87 -6.75% 42K

| -15.48% | O: -0.21% H: 2.62% C: 1.05%
als symposium biomarker therapeutics

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
Published: 2024-04-08 (Crawled : 13:30) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K

Professional, Scientific, and T...

| -10.67% | O: 0.28% H: 0.0% C: -3.92%
management therapeutics financial

AffyImmune Therapeutics Announces Clinical and Regulatory Advisory Board to Support Development of AIC100 in Solid Tumors
Published: 2024-04-08 (Crawled : 13:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K

Manufacturing

| Email alert Add to watchlist
aic100 tumors therapeutics

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
Published: 2024-04-08 (Crawled : 12:30) - prnewswire.com
CALT | News | $17.65 3.8K

Health Technology

| -18.4% | O: -1.06% H: 3.5% C: 0.51%
congress world nefecon therapeutics

Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
Published: 2024-04-08 (Crawled : 12:30) - biospace.com/
NVO | $122.71 -0.03% 0.17% 5M

Health Technology

| -0.35% | O: 1.62% H: 0.5% C: 0.36%
conference therapeutics

Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6156 2.69% 2.62% 100K

Health Care and Social Assistan...

| -14.29% | O: -2.0% H: 2.61% C: 2.21%
patent technology therapeutics

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
CTMX | $1.67 -3.47% -3.59% 510K

Health Technology

| -9.93% | O: 1.21% H: 0.48% C: -1.44%
cx-2051 first tumors therapeutics advanced study

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
CCCC | $6.74 -2.46% -2.52% 1.7M

Health Technology

| -9.79% | O: -1.57% H: 0.0% C: 0.0%
cft1946 association approved cancer care research preclinical for meeting therapeutics

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
Published: 2024-04-08 (Crawled : 12:00) - biospace.com/
BCLI | $0.5384 4.69% 4.48% 1M

Health Technology

| -24.16% | O: -0.37% H: 0.0% C: 0.0%
update cell nurown program therapeutics

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
TCRX | $6.8 -1.73% 230K

Professional, Scientific, and T...

| -3.57% | O: 3.14% H: 1.8% C: 1.66%
medical therapeutics

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
KYMR | $34.44 -1.94% 390K

Health Technology

| -1.07% | O: 3.38% H: 0.0% C: -0.9%
association cancer research for meeting therapeutics

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
MRKR | $4.25 3.65% 15K

Consumer Services

| -11.86% | O: -5.73% H: 5.86% C: 2.17%
hope city global medical therapeutics study

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann
Published: 2024-04-08 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 0.01% | O: 2.24% H: 0.0% C: -0.8%
SNY | News | $46.385 2.19% 3M

Health Technology

| -3.02% | O: 0.84% H: 0.0% C: 0.0%
therapeutics

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
BDTX A | $5.26 -0.76% 370K

Health Technology

| 8.03% | O: 5.22% H: 3.44% C: 2.1%
bdtx-1535 association presentation cancer research for meeting therapeutics

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
Published: 2024-04-05 (Crawled : 21:00) - globenewswire.com
ELTX | $8.465 2.86% 2.78% 28K

| Email alert Add to watchlist
plify-201 cell ongoing preclinical meeting eli-002 therapeutics response study

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
Published: 2024-04-05 (Crawled : 21:00) - globenewswire.com
HOWL | $5.91 0.68% 0.68% 120K

Professional, Scientific, and T...

| Email alert Add to watchlist
wtx-518 preclinical meeting therapeutics results

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
Published: 2024-04-05 (Crawled : 20:00) - globenewswire.com
NBSE | $0.411 -5.21% -5.5% 89K

Health Technology

| Email alert Add to watchlist
nasdaq therapeutics